Albany, NY (PRWEB) June 04, 2014
Global And China Tire Mold Industry Report, 2013-2014
The Chinese tire mold industry prosperity rose again in 2013, with annual sales approximating RMB3.565 billion, up 18.44% YoY, mainly because domestic tire companies successively proposed and expanded tire projects against a sharp decline of rubber prices in 2013, which pulled the tire mold demand.
To Read the Complete Report with Toc Visit: http://www.marketresearchreports.biz/analysis-details/global-and-china-tire-mold-industry-report-2013-2014
Judging from the earnings of key enterprises, China’s major tire mold enterprises showed varying degrees of growth in sales in 2013, of which, Shandong Himile Mechanical Science & Technology Co., Ltd. as the tire mold industry leader performed outstandingly, its sales from tire mold rose 57.11% YoY to RMB1.057 billion; followed by Greatoo Inc. whose tire mold sales attaining RMB468 million, up 14.04% YoY.
The high-speed growth in Himile’s tire mold business was mainly owing to its constantly-growing revenue from export sales, which accounted for 40.11% of the company’s total revenue in 2013, 2.96 percentage points higher than 2012, with CAGR up to 35% (2011-2013).
Meanwhile, Greatoo also continued to increase its investment in the tire mold business. In 2011, Greatoo put USD23 million into the radial tire mold production base construction in India; the project, put into production in 2012, now occupies about 30% share of India’s high-end tire mold market, with business radiation to the entire Southeast Asia. In July 2013, the “Large OTR and Special Tire Mold Expansion Project” went into operation, and brought benefit of RMB6.8355 million for the company that year.
Click Here To Download Detail Report: http://www.marketresearchreports.biz/sample/sample/206672
Both Himile and Greatoo are actively moving into new areas and creating new profit growth points while constantly developing their main business. The former thorough the acquisition of the Group company’s assets expanded new business; the latter extended to the upper steam of the industry chain.
On December 12, 2013, Himile purchased large gas turbine parts processing business projects and assets of Himile Machanical Manufacturing Co., Ltd. under the Group company with RMB114 million.
By virtue of the higher product and technical level of molds, Chinese tire mold enterprises will continue to enhance their comprehensive strength in the future. In the context of China’s ceaselessly-growing production and ownership of cars, its tire mold industry is bound to keep steady growth.
Breast Cancer Therapeutics In Major Developed Markets To 2020 - Approval Of Novel Therapies To Support Continued Dominance Of HER2 Targeted Drugs
MarketResearchReports.Biz presents this most up-to-date research on "Research Report On Breast Cancer Therapeutics In Major Developed Markets" To 2020 - Approval Of Novel Therapies To Support Continued Dominance Of HER2 Targeted Drugs
Business intelligence provider, has released its latest research: ‘Breast Cancer Therapeutics in Major Developed Markets to 2020 – Approval of Novel Therapies to Support Continued Dominance of HER2 Targeted Drugs ’, which provides in-depth analysis of breast cancer therapeutics market within the eight major geographies of the US, Canada, the top five geographies in Europe (the UK, France, Germany, Spain and Italy) and Japan. The report provides an estimation of market size for 2013, along with market forecast until 2020. It also covers disease epidemiology, treatment algorithms, treatment patterns, in-depth analysis of the pipeline, and deal analysis. The breast cancer therapeutics market in the eight major markets – The US, The UK, France, Germany, Spain, Italy, Japan and Canada – was worth $9.2 billion in 2013, and is expected to grow at a Compound Annual Growth Rate (CAGR) of 5.1% to $13.1 billion by 2020. The US had the largest market in 2013, valued at $5.5 billion, equivalent to a global share of 59%, followed by Japan with $871.5m or 9.4% and Italy with $668.5m or 7.2%. Canada had the lowest market share and value of the leading eight at 2.9% and $268.4m, but is expected to witness rapid growth over the forecast period with a CAGR of 6.7%. This will only be surpassed by Japan, which is expected to witness growth at a CAGR of 6.9%.
Visit Complete Report Here: http://www.marketresearchreports.biz/sample/sample/206658
The report analyzes treatment usage patterns, market characterization, pipeline analysis and key licensing and co-development deals in the breast cancer in the major developed markets.
The report includes:
MarketResearchReports.Biz presents this most up-to-date research on "Research Report On Anti-Hypertensive Therapeutics In Major Developed Markets" To 2020 - Increased Uptake Of Combination Therapies To Offset Effects Of Key Patent Expiries
Business intelligence provider, has released its latest research: ‘Anti-Hypertensive Therapeutics in Major Developed Markets to 2020 – Increased Uptake of Combination Therapies to Offset Effects of Key Patent Expiries ’, which provides in-depth analysis of hypertension therapeutics market within the eight major geographies of the US, the top five European countries (the UK, France, Germany, Spain and Italy), Japan and Canada.
Visit Complete Report Here: http://www.marketresearchreports.biz/sample/sample/206657
The report provides an estimation of market size for 2013, along with market forecast until 2020. It also covers disease epidemiology, treatment algorithms, treatment patterns, in-depth analysis of the pipeline, and deal analysis. The value of the hypertension market in the major developed markets amounted to an estimated $40.0 billion in 2013 and is expected to decline during the forecast period at a negative Compound Annual Growth Rate (CAGR) of 0.9% to $37.6 billion in 2020, with growth expected from 2013 to 2017 at a CAGR of 2.6% and a decline thereafter. The initial growth will be due to the increased penetration of fixed-dose combination drugs (Amturnide, Exforge Tribenzor, Azor, Tekturna HCT, Edarbyclor, Twynsta, Benicar HCT, Micardis Plus, Tekamlo, Valturna), a rise in the prevalence population from 181 million to 190 million at a CAGR of 0.6%, and two new expected launches in the pipeline (azilsartan + amlodipine, and AHU377+ valsartan). However, due to the expiry of the exclusivity of major drugs both before and during the forecast period (Cozaar in 2010; Diovan, Avapro and Atacand in 2012; Exforge in 2014; Benicar in 2016; and Tekturna and Tekturna HCT in 2018), increased generic penetration and a low diagnosis rate, the market will decline from 2017.
The report analyzes treatment usage patterns, market characterization, pipeline analysis and key licensing and co-development deals in the hypertension in the major developed markets.
The report includes:
MarketResearchReports.biz is the most comprehensive collection of market research reports. MarketResearchReports.Biz services are specially designed to save time and money for our clients. We are a one stop solution for all your research needs, our main offerings are syndicated research reports, custom research, subscription access and consulting services. We serve all sizes and types of companies spanning across various industries.
90 Sate Street, Suite 700
Albany, NY 12207
USA – Canada Toll Free: 866-997-4948